QSV Biologics has signed a second contract with Tissue Therapies Ltd. for the cGMP manufacture of clinical quantities of synthetic Vitroonectin and a single protein, chimeric form of VitroGro, called VitroGro-1. Tissue therapies will use these materials in preclinical and clinical trials early next year. Under the agreement QSV will be responsible for technology transfer and cGMP production in QSV’s licensed manufacturing facility. Terms of the final manufacturing contract have not been di...